A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects

Optimising migraine treatment: from drug-drug interactions to personalized medicine

(2019) Leda Marina Pomes et al.   JOURNAL OF HEADACHE AND PAIN

Emerging Treatment Targets for Migraine and Other Headaches

(2019) Zachariah Bertels et al.   HEADACHE

Migraine headache: Is it only a neurological disorder? Links between migraine and cardiovascular disorders

(2019) Dandan Chen et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80

(2018) Isaac J Dripps et al.   BRITISH JOURNAL OF PHARMACOLOGY

Tolerance to high-internalizing δ opioid receptor agonist is critically mediated by arrestin 2

(2018) Ana Vicente-Sanchez et al.   BRITISH JOURNAL OF PHARMACOLOGY

The pathophysiology of migraine: implications for clinical management

(2018) Andrew Charles   LANCET NEUROLOGY

CGRP as the target of new migraine therapies — successful translation from bench to clinic

(2018) Lars Edvinsson et al.   Nature Reviews Neurology

Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Lars Jacob Stovner et al.   LANCET NEUROLOGY

Delta opioid receptor agonists are effective for multiple types of headache disorders

(2018) Laura S. Moye et al.   NEUROPHARMACOLOGY

Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development

(2017) Viola Spahn et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action

(2017) Jonathan Jia Yuan Ong et al.   Neurotherapeutics

Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures

(2015) Paul Chu Sin Chung et al.   BEHAVIOURAL BRAIN RESEARCH

Why pharmacokinetic differences among oral triptans have little clinical importance: a comment

(2010) Anna Ferrari et al.   JOURNAL OF HEADACHE AND PAIN